

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Health Technology Evaluation

Capivasertib with fulvestrant for treating hormone receptor-positive HER2negative advanced breast cancer after endocrine treatment ID6370

Provisional Stakeholder List


Consultees	Commentators (no right to submit or appeal)
Company	General
CompanyAstraZeneca (capivasertib)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency for Equality Breast Cancer Now	Board of Community Health Councils in Wales
Breast Cancer UK	British National Formulary
Cancer Black Care	Care Quality Commission
Cancer Equality Holon Bolloon Concer Charity	 Department of Health, Social Services and Public Safety for Northern Ireland
Helen Rollason Cancer Charity Independent Cancer Potients Value Independent Can	
Independent Cancer Patients Voice Macmillan Cancer Support	Healthcare Improvement ScotlandMedicines and Healthcare products
Macmillan Cancer Support Maggie's Cantrage	Regulatory Agency
Maggie's Centres Make 2nde Count	 National Association of Primary Care
Make 2nds Count Maria Curia	
Marie Curie	National Pharmacy AssociationNHS Confederation
MET UP UK	
South Asian Health Foundation	14/11/0
Specialised Healthcare Alliance	_
Tenovus Cancer Care	Welsh Health Specialised Services Committee
Healthcare professional groups	
Association of Breast Surgery	Possible comparator companies
Association of Cancer Physicians Delitable Conjecture Conjecture	 Amarox (anastrozole, capecitabine, letrozole)
British Geriatrics Society British Institute of Redialogy	AstraZeneca (anastrozole, fulvestrant)
British Institute of Radiology British Payabasaid Openiany Society	Aurobindo Pharma – Milpharm
British Psychosocial Oncology Society British Openlary Pharmague	(tamoxifen)
British Oncology Pharmacy Association	Bristol Laboratories Ltd (anastrozole,
	letrozole)
British Society of Interventional Radiology	Bristol Myers Squibb Pharmaceuticals (paclitaxel)
Cancer Research UK	,
Royal College of General Practitioners	Cipla EU (fulvestrant, letrozole) Croscont Pharma Ltd (apastrozola)
Royal College of Nursing	 Crescent Pharma Ltd (anastrozole, letrozole)
Royal College of Pathologists	
Royal College of Physicians	 Dr. Reddy's Laboratories (capecitabine, everolimus, fulvestrant, letrozole)
Royal College of Radiologists	everolimus, ruivestrami, letrozole)

Provisional stakeholder list for the evaluation of capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370 Issue date: March 2024



Consultees Commentators (no right to submit or appeal) Royal Pharmaceutical Society Eli Lilly (abemaciclib) Royal Society of Medicine Ethypharm (everolimus) Genus Pharmaceuticals (fulvestrant) Society and College of Radiographers **UK Breast Cancer Group** Glenmark Pharmaceuticals (capecitabine, exemestane, fulvestrant, **UK Clinical Pharmacy Association** letrozole) **UK Oncology Nursing Society** Hospira UK (docetaxel, gemcitabine, Others paclitaxel) Manx Healthcare Ltd (anastrozole, Department of Health and Social Care letrozole) NHS England Medac GmbH (vinorelbine) Medical Valley (fulvestrant) Mylan (anastrozole, exemestane, tamoxifen) Morningside Healthcare Ltd (anastrozole, capecitabine, exemestane) Novartis (alpelisib, everolimus, ribociclib, letrozole) Pfizer (docetaxel, exemestane, palbociclib, paclitaxel) Pierre Fabre (vinorelbine) Ranbaxy, a Sun Pharmaceuticals company (anastrozole, fulvestrant, gemcitabine, letrozole) Rivopharm (exemestane) Rosemont Pharmaceuticals (tamoxifen) Sandoz (anastrozole, everolimus, fulvestrant) Seacross Pharmaceuticals (docetaxel, paclitaxel) Synchrony Pharma (gemcitabine) Teva UK (anastrozole, everolimus, fulvestrant, paclitaxel, tamoxifen) Tillomed Laboratories (tamoxifen) Wockhardt UK (tamoxifen) Zentiva (exemestane, fulvestrant) Relevant research groups **Against Breast Cancer Breast Cancer Hope** Cochrane Breast Cancer Group Cochrane UK Genomics England Institute of Cancer Research

Provisional stakeholder list for the evaluation of capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370 Issue date: March 2024



Consultees	Commentators (no right to submit or appeal)
	 MRC Clinical Trials Unit National Institute for Health Research Pro-Cancer Research Fund
	 Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.